Perrigo Steers Through Transportation Obstacles, Soaring Shipping Costs From COVID-19
Divesting ScarAway Wound-Care Brand Required For US FTC Approval Of HRA Acquisition
Perrigo largely has resolved distribution problems, but shipping freight costs still are much higher than pre-pandemic and it must divest a wound-care brand before US regulators sign off on acquisition of HRA Pharma, says CEO Murray Kessler during J.P. Morgan conference.
You may also be interested in...
British consumers can now buy three Mederma scar-care products in the UK via Amazon and Superdrug thanks to a recent launch by France's HRA Pharma.
Alliance Pharma has delivered on its commitment to expand its US operations with a deal for Perrigo's ScarAway and Kelo-cote brands. For Perrigo, the divestment brings its acquisition of HRA Pharma a step closer by satisfying competition concerns.
Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020. More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.